Health News Articles

Excerpts of key news articles on

Below are key excerpts of revealing news articles on health from reliable news media sources. If any link fails to function, a paywall blocks full access, or the article is no longer available, try these digital tools.

For further exploration, delve into our comprehensive Health and Food Corruption Information Center.

Note: Explore our full index to revealing excerpts of key major media news articles on dozens of engaging topics. And read excerpts from 20 of the most revealing news articles ever published.

Consumers around the country will soon know just by looking at the packaging of popular brands such as Cocoa Puffs cereal or Yoplait yogurt whether or not they contain genetically modified ingredients. Their maker, General Mills, plans to make that information visible on its products nationwide. Other major food companies have since followed, including Kellogg, ConAgra and candy maker Mars. Campbell Soup publicized the same decision in January. The companies are all responding to a Vermont law requiring the labelling of genetically modified foods starting in July, and to pressure from consumers and advocacy groups to reveal more information about controversial ingredients. Between 70% and 80% of packaged food in the US contains ingredients from genetically modified organisms. A genetically modified organism is created in a laboratory by taking genes from one species and inserting these genes into another to breed certain characteristics. Big food companies have historically fought mandatory labelling. They worry that genetic manipulation creates an impression that the food is unnatural or unhealthy. Meanwhile, anti-GMO advocacy groups, such as Center For Food Safety, and food makers who say they don’t use GMOs, including Plum Organics and Nature’s Path, also cast the fight as an issue of transparency, and accuse food makers of hiding important information from the public.

Note: 64 countries now require labelling of GM ingredients. When will the US give its citizens the right to know? For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

Doctors at the University Hospitals of Cleveland see an immediately recognizable symbol pop up alongside certain drugs when they sign in online these days to prescribe medications for patients: $$$$$. The dollar signs, affixed by hospital administrators, carry a not-so-subtle message: Think twice before using this drug. Pick an alternative if possible. The ... approach is just one of the strategies hospitals nationwide are using to try to counter drug costs. The increases often involved brand-name drugs with little or no competition as well as commonly used generics around for decades. Among those tagged were Nitropress and Isuprel, injectable heart medications that are a staple at many hospitals. Their 2015 list prices rose more than 200 percent and 500 percent, respectively. Hospital officials around the United States point to similar experiences, saying their predicament illustrates one dimension of a broken prescription-drug system. A recent Bloomberg Business survey of about 3,000 brand-name prescription drugs found that prices had more than doubled for 60 medications since December 2014 and at least quadrupled for 20. Prices for many other drugs continued to rise at 10 percent or more annually. “The patient doesn’t initially see the price increase,” said Scott Knoer, chief pharmacy officer at the Cleveland Clinic. “But it raises the cost for the hospital. Eventually, it catches up and it raises the cost for insurance companies, which is passed on to employers, employees and taxpayers.”

Note: For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.

Several EU countries could scupper plans by the European commission to approve the relicensing of a weedkiller linked to cancer. The vote to relicense glyphosate, a key ingredient in herbicides such as Monsanto’s multibillion-dollar brand Roundup, had been scheduled at a two-day meeting of experts from the EU’s 28 member states, which begins on Monday. But officials are now saying that they may postpone the vote rather than lose it, raising the prospect of a legal limbo for glyphosate, the licence for which runs out in June. France, the Netherlands and Sweden have all said they will not support an assessment by the European food safety authority (Efsa) that glyphosate is harmless. That ruling ran counter to findings by the WHO’s cancer agency that glyphosate was “probably carcinogenic to humans”, causing a bitter row over scientific methodology and industry influence. The Swedish environment minister, Ĺsa Romson, said: “We won’t take risks with glyphosate and we don’t think that the analysis done so far is good enough. We will propose that no decision is taken until further analysis has been done and the Efsa scientists have been more transparent about their considerations.” An Efsa panel based its recommendation that glyphosate was safe ... on six industry-funded studies that have not been fully published. Glyphosate use has been banned or restricted in large parts of Europe because of alleged links to a host of health problems, ranging from birth defects and kidney failure to coeliac disease, colitis and autism.

Note: The overlap between the GMO industry and European regulators has become increasingly controversial. For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

The same strategy that Martin Shkreli used to get away with a 5,000-percent price increase on an old drug is used by many other drugmakers. Before the price hike that made him infamous, the former CEO of Turing Pharmaceuticals had to ensure that no competitor would be able to launch a cheaper version of Daraprim, the 60-year-old anti-infection pill that is no longer under patent. Shkreli had the perfect weapon: a tightly-controlled distribution system which would make it virtually impossible for a competitor to obtain enough Daraprim to develop their own version. Many larger drugmakers have also turned drug distribution into a powerful tool against competition. The strategy takes advantage of a simple fact: If generic drugmakers can't get their hands on the original product, they cannot perform the tests needed to develop a generic version. When the original drugmaker controls the drug's distribution, they can simply refuse to sell. The effect on patients is higher prices for drugs. At least 40 drugs worth an estimated $5.4 billion are sheltered from competition by distribution hurdles, according to a study commissioned by the Generic Pharmaceutical Association, an industry trade group. The Food and Drug Administration is aware of the misuse of distribution programs. The agency does not penalize companies for the practice.

Note: For more excellent information on drug prices hikes, read this penetrating article in the Daily Beast. For more along these lines, see concise summaries of deeply revealing big Pharma profiteering news articles from reliable major media sources.

Johnson & Johnson must pay $72 million to the family of a woman who blamed her fatal ovarian cancer on the company’s talcum powder in the first state-court case over the claims to go to trial. Jurors in St. Louis on Monday concluded J&J should pay $10 million in compensatory damages and $62 million in a punishment award to the family of Jackie Fox, who died of ovarian cancer last year after using Johnson’s baby powder ... for years. It’s the first time a jury has ordered J&J, the world’s largest maker of health-care products, to pay damages over claims that it knew decades ago that its talc-based products could cause cancer and failed to warn consumers. J&J is facing about 1,200 suits claiming studies have linked its Johnson’s Baby Powder and its Shower-to-Shower product to ovarian cancer. Women contend the company knew of the risk and failed to warn customers. J&J marketed its Shower to Shower brand talc for feminine hygiene. One 1988 ad promised “just a sprinkle a day keeps odor away.” Cornstarch has been widely substituted for talc as an absorbent in baby powder and feminine hygiene products. The American Cancer Society advised in 1999 that women use cornstarch-based products in the genital area. J&J, which introduced a baby powder using cornstarch in the 1970s, continues to offer products that include talc. A federal jury in North Dakota found in 2013 that a woman’s use of its talc-based body powder contributed to her developing ovarian cancer, [but] awarded no damages.

Note: For more along these lines, see concise summaries of deeply revealing news articles on corporate corruption and health.

Scientists have identified more than 200 industrial chemicals - from pesticides, flame retardants, jet fuel - as well as neurotoxins like lead in the blood or breast milk of Americans, indeed, in people all over our planet. These have been linked to cancer, genital deformities, lower sperm count, obesity and diminished I.Q.. Medical organizations ... have demanded tougher regulations or warned people to avoid them. They have all been drowned out. Chemical companies, by spending vast sums on lobbying - $100,000 per member of Congress last year - block serious oversight. Almost none of the chemicals in products we use daily have been tested for safety. “Industrial chemicals that injure the developing brain” have been linked to conditions like autism and attention deficit hyperactivity disorder, noted The Lancet Neurology, a peer-reviewed medical journal. Yet we still don’t have a clear enough sense of what is safe, because many industrial chemicals aren’t safety tested before they are put on the market. Meanwhile, Congress has dragged out efforts to strengthen the Toxic Substances Control Act and test more chemicals for safety. The President’s Cancer Panel recommended that people eat organic if possible, filter water and avoid microwaving food in plastic containers. All good advice, but that’s like telling people to avoid cholera without providing clean water. And that’s why we need another public health revolution in the 21st century.

Note: For more along these lines, see concise summaries of deeply revealing news articles about corruption in government and in the corporate world. Then explore the excellent, reliable resources provided in our Health Information Center.

Pediatric cardiologist Dr. Sandra Mattos had been collecting data on 100,000 newborns in the Brazilian state of Paraiba as part of her work. The microcephaly fears linked to the Zika virus drove her team to check back into hospital records for ... more than 1,600 babies born in the state in the last four years. "We were very, very surprised," Mattos said. Babies with mild microcephaly were present in the population dating back to at least 2012. Scientists think the original reports of 4,700 suspected cases were inflated by over-reporting that didn't stand up when specialists examined the babies. Lingering questions remain, including why more than 80 per cent of suspected microcephaly cases are confined to Brazil's northeast region. And why has microcephaly not appeared in other Latin American countries with similar climates, such as among the 2,100 pregnant women infected with Zika in Colombia? In Berlin, epidemiologist Dr. Christoph Zink has been charting publicly available data from the Zika virus outbreak in terms of when cases appeared, the geographic distribution and the continuous microcephaly epidemic. He proposes another potential explanation. "I would ask my toxicological colleagues in Brazil to please look very closely into the practical application of agrochemicals in their country," Zink said. Mattos said pesticides have been raised as a potential factor by her colleagues in Brazil.

Note: Another article describes a doctors group which has stated the increasing microcephaly may be caused by a larvacide. Notice how the media participates in creating fear of Zika around the world. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.

California may have closed a chapter in its bitter fight over mandatory vaccines for children, but a new billboard campaign by opponents of the state's pro-vaccination law shows the controversy is far from over. Billboards questioning the safety of vaccines have popped up over the past couple of months from Berkeley and San Francisco to North Fair Oaks. More went up in January in the San Jose area to coincide with Super Bowl 50. The billboards, [which] proclaim that vaccines pose serious health risks ... are the brainchild of Brandy Vaughan, founder of the Council for Vaccine Safety [and former] sales representative for Merck. Vaughan was an outspoken opponent of SB 277. The legislation, signed in June by Gov. Jerry Brown ... eliminated personal belief or religious exemptions to mandatory vaccines for school-age children. Though an effort to repeal the law fell apart, [mandatory] vaccinations continue to be a highly charged and divisive issue across the nation. Vaughan has raised $10,000 online for a dozen billboards in the Bay Area. "We're no longer the land of the free if we give up the choice of what we put in our body," said Vaughan. "My goal is to educate the public and encourage people to do their own research and connect the dots." She calls for tighter government regulation of vaccine-makers and suspects that America's growing vaccination regime is responsible for various health conditions.

Note: Vaughan has been severely intimidated, as she explains in this video. Here's another great video of her. To learn more about her courageous work, see this website and consider donating to her worthy cause. And watch an excellent 11-minute video of highly respected biochemist Garth Nicolson present evidence of the danger of Mycoplasma in vaccines. In a longer video Dr. Nicolson discusses biological warfare agents used against the public.

Brazil’s government is considering tightening the guidelines it currently gives doctors, hospitals, and health care providers for when to report infants born with abnormally small heads, a move intended to reduce the number of false alarms that it has received in wake of the Zika epidemic gripping Brazil. In the last few months, the nation has been grappling with a growing surge in medical reports of microcephaly, a rare condition in which babies are born with unusually small heads. According to data released this week by the Ministry of Health, there have been 4,783 reported cases since October last year. Before that, the nation had about 150 annually. But how many of the babies actually have microcephaly - and whether the condition was caused by the Zika virus - is still far from clear. Of the cases examined so far, 404 have been confirmed as having microcephaly. Only 17 of them tested positive for the Zika virus. Another 709 babies have been ruled out as having microcephaly, according to the government, underscoring the risks of false positives making the epidemic appear larger than it actually is. The remaining 3,670 cases are still being investigated. As is often the case with global health epidemics, the numbers have caused confusion. Some have wondered if Brazil was overstating the extent of its health crisis.

Note: Another article describes a doctors group which has stated the increasing microcephaly may be caused by a larvacide. For more along these lines, see concise summaries of deeply revealing news articles on the zika virus from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.

The mosquito-borne Zika virus is drawing global attention. Earlier today, the head of the World Health Organization said Zika is "spreading explosively." Brazil has reported more than 4,000 cases of babies born recently with microcephaly, a brain condition characterized by an abnormally small head that can lead to developmental issues or even death. That number compares with fewer than 150 cases in the country for all of 2014. The virus is mainly a health concern for women who are pregnant and it does not have long-lasting effects on most people. The virus is primarily transmitted through the Aedes aegypti mosquito. So far there is limited evidence on whether Zika can be transferred from mother to child. ​But because of the rash of microcephaly cases in Brazil, which spiked after the first confirmed case of Zika, this maternal link is "strongly suspected" and being closely studied. Only one in five of those infected with Zika show symptoms, which develop up to one week after being bitten. Most symptoms are mild, and ... can be easily treated with rest and plenty of fluids. Dr. Sumon Chakrabarti told CBC News, "the one thing to make very clear is that Zika, once it's out of your body, it's gone. It's not something like Hepatitis B or HIV that can stay in your body forever. "Overall, Zika is a very mild illness apart from what we think might be happening in pregnant women."

Note: Lots more fear mongering with this latest virus. Yet there is actually very little risk, with the possible exception of pregnant mothers, and even this is being exaggerated. Remember, powerful people want to keep us in fear, as that makes it easier to manipulate us. The swine flu, avian flu and ebola are prime examples of supposed "doomsday diseases" that turned out to harm relatively few. For more on how these diseases were manipulated and who profited, see concise summaries of deeply revealing major media news articles from reliable sources on this.

Water authorities across the US are systematically distorting water tests to downplay the amount of lead in samples. Water boards in cities including Detroit and Philadelphia, as well as the state of Rhode Island, have distorted tests by using methods deemed misleading by the Environment Protection Agency. The revelation comes as the growing crisis in Flint, Michigan, has prompted an emergency EPA order, the condemnation of Barack Obama and the resignation of a top agency official. “Gamed” tests help ensure that water utilities don’t breach federal lead and copper rules. Dr Yanna Lambrinidou, a Virginia Tech academic, has disclosed what she considers to be evidence of deceptive practices ... after she sat on an EPA taskforce that reviewed federal rules on lead and copper poisoning. The taskforce ended its work last year, shortly before the full extent of the city of Flint’s problems with smelly, brown water hit the headlines, with Lambrinidou criticising the final report for failing to step up protections. Several cities have advised residents to use questionable methods when conducting official tests for lead content. These include encouraging testers to run taps for several minutes to flush out lead from the pipes. Such methods have been criticized by the EPA for not providing accurate results. If the water was tested directly from lead pipes, up to 96 million Americans could be found to be drinking water with unsafe levels of lead.

Note: For more along these lines, see concise summaries of deeply revealing government corruption news articles from reliable major media sources.

Some Marketplace reports about vitamins and supplements published in November contained incorrect information, CBC has learned. Last fall, Marketplace commissioned lab testing for samples of fish oil, vitamin C and protein powder supplements to see if consumers are actually getting what they pay for. Based on those test results, Marketplace reported that Emergen-C and two protein powders: GNC Lean Shake 25 and Cytosport Muscle Milk failed to live up to label claims. However, subsequent re-testing of the samples has found that the lab results and analysis provided to Marketplace were incorrect, and that there is no evidence of problems with those products. The original lab tests were performed by an independent lab in Michigan, which is ISO-17025 accredited, registered with the U.S. Food and Drug Administration, and used by the supplement industry. The lab was recommended by Neil Thanedar, co-founder and CEO of LabDoor, a company that has products tested and makes those results public to help guide consumers about vitamins and supplements. CBC re-tested some of the products at other independent, accredited labs. None of them found problems with the samples. While Thanedar admits some of the lab results he provided to Marketplace were flawed, he was still unable to explain how the mistakes were made.

Note: Definitely something fishy going on here. For more along these lines, see concise summaries of deeply revealing health news articles from reliable major media sources. Then explore the excellent, reliable resources provided in our Health Information Center.

When does Big Pharma profiting become profiteering? This issue was the subject last month of a Senate Finance Committee investigation of pricing practices of Gilead Sciences Inc., a leading provider of hepatitis C medications. After examining 20,000 pages of internal company documents, looking at Medicaid data and interviewing health care experts, the authors concluded that the Foster City drugmaker “pursued a calculated scheme for pricing and marketing its hepatitis C drug based on one goal: maximizing revenue regardless of the human consequences.” With the hepatitis C virus affecting about 3 million people in the United States, the impact of Gilead’s pricing strategy is real, measurable - and devastating. With a 12-week course of Gilead’s Harvoni priced at nearly $100,000, taxpayer-funded Medicare Part D spent $4.6 billion on hepatitis C alone in the first half of 2015. When insurers refuse to pay for treatment, all but the wealthy are left at risk for cirrhosis, liver cancer and death. While anticipating record profits of $30 billion in 2015, Gilead virtually eliminated its medication assistance program. More than 90 percent of hepatitis C patients can achieve a cure with as little as one pill a day. But to realistically address this epidemic at current pricing levels would bankrupt our health care system. Pharmaceutical innovation holds great promise for the future of our health care system. But not if none of us can afford it.

Note: For more along these lines, see concise summaries of deeply revealing news articles about big pharma profiteering. Then read an in-depth essay titled "The Truth About Drug Companies" by acclaimed author Dr. Marcia Angell.

Abdel Gawad Ellabbad knows exactly how he was infected with hepatitis C. As a schoolboy in this Nile Delta rice-farming village, his class marched to the local clinic every month for injections against schistosomiasis, a parasitic disease spread by water snails. Six million Egyptians were infected with hepatitis C by unsterile needles during the country’s decades-long fight against schistosomiasis. The virus spread insidiously; today, at least 10 percent of Egyptians, nearly nine million people, are chronically infected, the highest rate in the world. But a grand experiment unfolding across the country may change all that. Pharmaceutical companies are testing ... a complicated deal to sell hepatitis drugs at a fraction of their usual cost. If [successful] the arrangement in Egypt may serve as a blueprint not just for curing hepatitis around the world, but also for providing other cutting-edge medicines to citizens in poor countries who could never afford them. The experiment here is about a year old and, while still fragile, appears to be headed for success. Mr. Ellabbad, for one, was finally cured of hepatitis this spring. An air-conditioning repairman, he took a three-month regimen that included sofosbuvir, first of the new generation of miracle drugs. The pills would have cost more than $84,000 in the United States. He got them free from the Egyptian government, which paid about $900. “Before, I felt like I was dying,” he said. “Now I feel like I’ve never felt before. Like I’m 35 again.”

Note: Explore a treasure trove of concise summaries of incredibly inspiring news articles which will inspire you to make a difference.

The world’s biggest animal “cloning factory” is due to open in China, producing one million calves a year, sniffer dogs and even genetic copies of the family pet. The center may cause alarm in Europe, where the cloning of animals for farming was banned in September due to animal welfare considerations. But Xu Xiaochun, chairman of Chinese biotechnology company BoyaLife that is backing the facility, dismissed such concerns. Interest in agricultural biotechnology has been rapidly increasing in China, where [beef prices] are said to have tripled from 2000 to 2013. Mr Xu said his new facility will clone racehorses and a handful of dogs for people with “emotional ties” to their pets, but its main focus was producing cattle. However, he appeared to be more excited about its ability to churn out sniffer dogs. “The dog has to be smart and obedient, strong, sensitive," he said. The factory, which will include a 15,000 square metre laboratory, an animal centre, a gene bank and an exhibition hall ... is due to open in the first half of next year. BoyaLife will operate the facility with its South Korean partner, Sooam Biotech, that runs a centre that can clone dogs for customers willing to pay $100,000 (Ł66,000), and has already produced more than 550 puppies. The new facility will initially produce 100,000 cattle embryos a year, eventually increasing to one million.

Note: For more along these lines, see concise summaries of deeply revealing GMO news articles from reliable major media sources.

The American Medical Association on Tuesday called for a ban on direct-to-consumer ads for prescription drugs and implantable medical devices, saying they contribute to rising costs and patients' demands for inappropriate treatment. Delegates at the influential group's policy-making meeting in Atlanta voted to adopt that as official policy as part of an AMA effort to make prescription drugs more affordable. It means AMA will lobby for a ban. "Today's vote in support of an advertising ban reflects concerns among physicians about the negative impact of commercially driven promotions and the role that marketing costs play in fueling escalating drug prices," said Dr. Patrice Harris, an AMA board member. According to data cited in an AMA news release, ad dollars spent by drugmakers have risen to $4.5 billion in the last two years, a 30 percent increase. Other data show prices on prescription drugs have climbed nearly 5 percent this year, Harris said in the news release. She also raised concern that advertising spurs use of newer brand-name drugs when other possibly lower-cost options might be just as good. "Direct-to-consumer advertising also inflates demand for new and more expensive drugs, even when these drugs may not be appropriate." The pharmaceutical industry opposes the AMA's stance.

Note: For more along these lines, see concise summaries of deeply revealing big pharma profiteering news articles from reliable major media sources. Then read an in-depth essay titled "The Truth About Drug Companies" by acclaimed author Dr. Marcia Angell.

Turing Pharmaceuticals chief executive Martin Shkreli found himself in the middle of a media firestorm last month as he adamantly defended his company's 4,000 percent drug price hike. Daraprim, which treats a life-threatening infection in patients with HIV/AIDS and other immune problems, was increased to $750 a pill, a move resoundingly decried. Now, another company will offer a Daraprim alternative, at just $1 a pill. It's not an exact replica of Daraprim. San Diego-based Imprimis Pharmaceuticals announced Thursday that it is selling pills containing a "customizable compounded formulation" of pyrimethamine and leucovorin, both ingredients in Daraprim. The Food and Drug Administration doesn't approve compounded drugs, such as this one offered by Imprimis. Typically, compounded drugs are prescribed to patients who can't take FDA-approved drugs, such as for those who are allergic to an inactive ingredient. Compounded drugs are no stranger to controversy; a compounding pharmacy was at the heart of a deadly meningitis outbreak in 2012 that killed 64 people and sickened more than 600. Federal legislators subsequently tightened regulations over such companies. And compounded drugs can be very pricey, too. But it appears the Daraprim alternative compound was not born out of a physical inability to use Daraprim, but a financial one.

Note: Read more about Turing Pharmaceuticals' outrageous Daraprim price-hike. Those in charge of the compounding pharmacy mentioned above were charged with homicide, but when a meningitis outbreak killed 11 children in an illegal Nigerian drug trial conducted by Pfizer, no one at Pfizer was charged with a crime. For more along these lines, see concise summaries of deeply revealing news articles about big pharma corruption.

No industry has aligned itself more closely with the breast cancer movement than the cosmetics industry. Yet while they prominently claim to care about women with breast cancer, their pink ribbon products all too often actually increase risk of the disease. Look Good Feel Better is a ... program run by the Personal Care Products Council (PCPC), the largest national trade group for the cosmetics industry, and the American Cancer Society (ACS), the nation’s largest cancer charity. They hold free workshops that give beauty tips and complimentary makeup kits to women in cancer treatment. Member companies of the [PCPC] donate cosmetic products for the kits given to cancer patients. The American Cancer Society administers the program nationwide. Many of the Look Good Feel Better kits contain ... carcinogens and hormone disruptors. These chemicals ... increase breast cancer risk, [and] interfere with breast cancer treatment. Most breast cancers are hormone-driven and common treatments target the body’s hormonal system. Some hormone disruptors – including methylparaben, which is in concealer and face wipes the ACS is giving to cancer patients – have been shown in a lab to interfere with Tamoxifen, a common hormonal breast cancer treatment. While the European Union has banned 1,300 chemicals from use in cosmetics, the United States has banned fewer than one dozen. The Personal Care Products Council spends millions of dollars lobbying against cosmetic safety regulations.

Note: Read about another example of egregious "pinkwashing" by a fracking company. And watch a promising new documentary on suppressed cancer cures. For more, see concise summaries of deeply revealing corporate corruption news articles, or learn about the promising cancer research too often suppressed in mainstream media.

Quebec-based Valeant Pharmaceutical's price hikes of drugs long off patent has raised the ire of U.S. legislators and frustrated Canadian physicians. Democrats on the House of Representatives committee on oversight and government reform sent a letter Monday to the committee's Republican chairman seeking a subpoena that would force Valeant to turn over documents tied to the U.S. price hikes of two heart drugs. In the U.S., the price of Isuprel or Isoprenaline increased 2,500 per cent and Nitropress went up 1,700 per cent in three years, as the drug changed hands. Valeant purchased the rights to both heart drugs from Marathon Pharmaceuticals in February. As huge overnight drug price hikes becomes an election issue in the U.S., some doctors in Canada struggle to get other prices rolled back. In late 2013, Valeant Canada announced that as of January 2014, the price of a one-month supply of Syprine would match the U.S. price of roughly $13,244, or about 13 times higher than the previous price. The medication makes the difference between a full and productive life or a downward course of increasing liver and neurological disease. For physicians, the price increase put them in the position of having to tell patients their disease can be managed or cured but at an out-of-pocket price of $200,000 a year for the rest of their lives.

Note: For more along these lines, see concise summaries of deeply revealing news articles about big pharma profiteering from reliable major media sources.

Cancer patients need to be prepared for serious side effects from chemotherapy, and hospitalization is one that happens much more often in the real world than in drug trials, according to a new study. Researchers found that people with advanced lung cancer receiving chemotherapy in real-world settings were almost eight times more likely to be hospitalized during treatment than those participating in clinical trials. What's more, very few clinical trials even report how often participants are hospitalized during the research, the study authors found. "Clinical trials should be routinely reporting their hospitalization rates so we know what to expect," said senior author Dr. Monika Krzyzanowska, a medical oncologist at the Princess Margaret Cancer Center in Toronto, Canada. Krzyzanowska and her colleagues write in JAMA Oncology that the number of times a person goes to the hospital with treatment complications is important to the patient and to the hospital. The researchers suggest several possible explanations for the differences in hospitalization rates. First, the patients in highly selective clinical trials are different from real-world patients. In this study, people receiving chemotherapy in real-world settings were also older, on average, than those in clinical trials.

Note: While big pharma profits from hiding the negative effects of their drugs, there is some promising cancer research underway, some of which is being suppressed to keep the cash cow flowing for big pharma.

Important Note: Explore our full index to revealing excerpts of key major media news articles on several dozen engaging topics. And don't miss amazing excerpts from 20 of the most revealing news articles ever published.